What’s the current market cap for Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical (RARE) has a market cap of $2.6bn as of June 19, 2026.

What is the P/E ratio for Ultragenyx Pharmaceutical stock?

The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of June 19, 2026.

Does Ultragenyx Pharmaceutical stock pay dividends?

No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of June 19, 2026.

When is the next Ultragenyx Pharmaceutical dividend payment date?

Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.

What is the beta indicator for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Ultragenyx Pharmaceutical stock | $RARE Share Price

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Ticker

$RARE

Sector

Health

Primary listing

NASDAQ

Employees

1,371

Headquarters

Novato, United States

Website

www.ultragenyx.com

RARE Metrics

BasicAdvanced

$2.6bn

-

-$6.11

0.39

-

What the Analysts think about RARE

Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.

Bulls say / Bears say

FDA accepted the resubmitted BLA for UX111 gene therapy for Sanfilippo syndrome type A and set a PDUFA action date of September 19, 2026, positioning Ultragenyx for a potential near-term approval in an indication with no approved therapies (GlobeNewswire).

Interim Phase 3 data for DTX301 in OTC deficiency demonstrated a statistically significant 18% reduction in 24-hour plasma ammonia versus placebo (p=0.018) at Week 36, validating clinical efficacy and de-risking the program ahead of full readout (GlobeNewswire).

Ultragenyx reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million (excluding potential new product revenues), signaling management’s confidence in continued commercial momentum across its rare disease portfolio (GlobeNewswire)

Q1 2026 revenue of $136 million fell short of the consensus estimate of $160.7 million, reflecting softer-than-expected demand for Crysvita and Dojolvi (Investing.com).

Net loss widened to $185 million in Q1 2026 from $151 million a year earlier, driven by higher R&D spending and a $30 million restructuring charge, underscoring persistent profitability challenges (GlobeNewswire).

Cash, cash equivalents and marketable securities declined 27.6% to $534 million as of March 31, 2026 from $737 million at December 31, 2025, indicating substantial cash burn and raising funding runway concerns before break-even (GlobeNewswire)

Data summarised monthly by Lightyear AI. Last updated on 17 Jun 2026.

RARE Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

RARE Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

RARE News

AllArticlesVideos

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Newsfile Corp·3 weeks ago

Rare disease families find roadmap to drug development at bootcamps

CNBC·1 month ago

There's a New Rare-Earth Stock. Here's What Makes It Stand Out.

Barrons·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Ultragenyx Pharmaceutical

Ticker

Employees

RARE Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about RARE

Analyst Ratings

Bulls say / Bears say

RARE Financial Performance

Income Statement

RARE Earnings Performance

Earnings per share (EPS)

RARE News

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Rare disease families find roadmap to drug development at bootcamps

There's a New Rare-Earth Stock. Here's What Makes It Stand Out.

Buy $RARE

Lightyear

Legal

Work with us

Bulls say / Bears say

Ultragenyx Pharmaceutical/$RARE

About Ultragenyx Pharmaceutical

Ticker

Employees

RARE Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about RARE

Analyst Ratings

Bulls say / Bears say

RARE Financial Performance

Income Statement

RARE Earnings Performance

Earnings per share (EPS)

RARE News

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Rare disease families find roadmap to drug development at bootcamps

There's a New Rare-Earth Stock. Here's What Makes It Stand Out.

What’s the current market cap for Ultragenyx Pharmaceutical stock?

What is the P/E ratio for Ultragenyx Pharmaceutical stock?

Does Ultragenyx Pharmaceutical stock pay dividends?

When is the next Ultragenyx Pharmaceutical dividend payment date?

What is the beta indicator for Ultragenyx Pharmaceutical?

Bulls say / Bears say